Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-CD
2021-002869-18Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing ABBV-154 with Placebo (2 arms). Primary endpoint: Endoscopic response at Week 12. Started Sep 2021; status: terminated.
02
Drugs
ABBV-154
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2021-002869-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002869-18.